[go: up one dir, main page]

MX2022012592A - Construcciones de citocinas activables y composiciones y metodos relacionados. - Google Patents

Construcciones de citocinas activables y composiciones y metodos relacionados.

Info

Publication number
MX2022012592A
MX2022012592A MX2022012592A MX2022012592A MX2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A MX 2022012592 A MX2022012592 A MX 2022012592A
Authority
MX
Mexico
Prior art keywords
activatable
methods
related compositions
cytokine
constructs
Prior art date
Application number
MX2022012592A
Other languages
English (en)
Inventor
Sayantan Mitra
Nicole G Lapuyade
Hikmat Haizar Assi
Madan M Paidhungat
Dylan L Daniel
Scolan Erwan Le
Walter A Bogdanoff
Na Cai
Hsin Wang
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of MX2022012592A publication Critical patent/MX2022012592A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

En la presente se proporcionan construcciones de citocinas activables que incluyen: (a) una primera construcción de monómero que comprende una primera proteína de citocina madura (CP1), un primer resto escindible (CM1) y un primer dominio de dimerización (DD1), en donde el CM1 está ubicado entre el CP1 y el DD1; y (b) una segunda construcción de monómero que comprende una segunda proteína de citocina madura (CP2), un segundo resto escindible (CM2) y un segundo dominio de dimerización (DD2), donde el CM2 está ubicado entre el CP2 y el DD2, donde: el CM1 y el CM2 funcionan como sustrato para una proteasa; el DD1 y el DD2 se unen entre sí; y donde la ACC está caracterizada por una reducción en al menos una actividad del CP1 y/o CP2 en comparación con un nivel de control de al menos una actividad del CP1 y/o CP2.
MX2022012592A 2020-04-10 2021-04-09 Construcciones de citocinas activables y composiciones y metodos relacionados. MX2022012592A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063008542P 2020-04-10 2020-04-10
US202163161889P 2021-03-16 2021-03-16
US202163164849P 2021-03-23 2021-03-23
PCT/US2021/026675 WO2021207669A1 (en) 2020-04-10 2021-04-09 Activatable cytokine constructs and related compositions and methods

Publications (1)

Publication Number Publication Date
MX2022012592A true MX2022012592A (es) 2022-12-07

Family

ID=75747127

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012592A MX2022012592A (es) 2020-04-10 2021-04-09 Construcciones de citocinas activables y composiciones y metodos relacionados.

Country Status (11)

Country Link
US (3) US11365233B2 (es)
EP (1) EP4133085A1 (es)
JP (1) JP2023520922A (es)
KR (1) KR20220167295A (es)
CN (1) CN115667523A (es)
AU (1) AU2021254283B2 (es)
BR (1) BR112022020440A2 (es)
CA (1) CA3174786A1 (es)
IL (1) IL297225A (es)
MX (1) MX2022012592A (es)
WO (1) WO2021207669A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022012592A (es) 2020-04-10 2022-12-07 Cytomx Therapeutics Inc Construcciones de citocinas activables y composiciones y metodos relacionados.
AU2022237504A1 (en) 2021-03-16 2023-10-05 Cytomx Therapeutics, Inc. Masked activatable cytokine constructs and related compositions and methods
WO2023034825A1 (en) 2021-08-30 2023-03-09 Cytomx Therapeutics, Inc. Method for determining protease activity in a biological sample
JP2024537101A (ja) * 2021-10-08 2024-10-10 シートムエックス セラピューティクス，インコーポレイテッド 活性化可能サイトカイン構成体ならびに関連する組成物及び方法
US20240116997A1 (en) 2022-02-23 2024-04-11 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
JP2025508988A (ja) * 2022-03-03 2025-04-10 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 副甲状腺ホルモン融合物をコードするウイルスベクター及び副甲状腺機能低下症の治療におけるその使用
US20250333539A1 (en) 2022-03-23 2025-10-30 Cytomx Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
US20250333487A1 (en) 2022-03-25 2025-10-30 Cytomx Therapeutics, Inc. Activatable dual-anchored masked molecules and methods of use thereof
EP4504782A2 (en) 2022-04-01 2025-02-12 CytomX Therapeutics, Inc. Cd3-binding proteins and methods of use thereof
WO2023192973A1 (en) 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
US20260015425A1 (en) 2022-08-01 2026-01-15 Cytomx Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
EP4565260A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
EP4565261A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
EP4565250A1 (en) 2022-08-01 2025-06-11 CytomX Therapeutics, Inc. Protease-cleavable substrates and methods of use thereof
WO2024030843A1 (en) 2022-08-01 2024-02-08 Cytomx Therapeutics, Inc. Protease-cleavable moieties and methods of use thereof
US20240067691A1 (en) * 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
US20240417436A1 (en) 2023-01-11 2024-12-19 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
CN120958015A (zh) 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
WO2024216170A2 (en) 2023-04-12 2024-10-17 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CN120936384A (zh) 2023-04-12 2025-11-11 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法
US20250197467A1 (en) 2023-08-23 2025-06-19 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
WO2025240659A2 (en) 2024-05-14 2025-11-20 Cytomx Therapeutics, Inc. Activatable constructs, compositions and methods
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026024841A1 (en) 2024-07-24 2026-01-29 Astellas Us Llc Bispecific antibodies that bind cd3 and muc1 and methods of use thereof

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
ATE139900T1 (de) 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2001091798A2 (en) 2000-06-01 2001-12-06 Universite Catholique De Louvain Tumor activated prodrug compounds
ES2288967T3 (es) * 2000-06-29 2008-02-01 Merck Patent Gmbh Reforzamiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citoquina por medio del tratamiento combinado por agentes que mejoran la incorporacion de inmunocitoquina.
US7465790B2 (en) 2000-10-09 2008-12-16 Isis Innovation, Inc. Therapeutic antibodies
AU2001293995B2 (en) 2000-10-09 2005-10-13 Cytomx Therapeutics, Inc. Therapeutic antibodies
US6942853B2 (en) * 2001-01-09 2005-09-13 Queen Mary And Westfield College Latent fusion protein
US20040109855A1 (en) 2002-07-23 2004-06-10 Herman Waldmann Therapeutic antibodies with reduced side effect
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
US20060024272A1 (en) 2004-07-29 2006-02-02 Large Scale Biology Corporation C-terminally truncated interferon
AU2006250068A1 (en) * 2005-05-26 2006-11-30 Schering Corporation Interferon-IGG fusion
US20090220529A1 (en) 2006-03-10 2009-09-03 Diatos, S.A. Anticancer Drugs Conjugated to Antibody via an Enzyme Cleavable Linker
CA3128656A1 (en) 2007-08-22 2009-02-26 The Regents Of The University Of California Activatable binding polypeptides and methods of identification and use thereof
WO2009079837A1 (en) 2007-12-18 2009-07-02 Hangzhou Jiuyuan Gene Engineering Co., Ltd. A pharmaceutical formulation containing recombinant human serum albumin-interferon alpha fusion protein
CN106995495A (zh) 2009-01-12 2017-08-01 希托马克斯医疗有限责任公司 修饰抗体组合物及其制备和使用方法
CN102481341B (zh) 2009-02-23 2017-05-17 希托马克斯医疗有限公司 蛋白原及其使用方法
US8734774B2 (en) 2010-04-02 2014-05-27 University Of Rochester Protease activated cytokines
KR101952460B1 (ko) 2010-12-03 2019-02-27 아다메드 파르마 에스.에이. 항암 융합 단백질
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2672974T3 (es) * 2012-06-01 2018-06-19 Ibc Pharmaceuticals, Inc. Complejos multiméricos con estabilidad in vivo, farmacocinética y eficacia mejoradas
RU2715232C2 (ru) 2013-09-25 2020-02-26 Сайтомкс Терапьютикс, Инк. Субстраты матриксной металлопротеиназы и другие расщипляемые фрагменты и способы их использования
CN114106099B (zh) * 2014-01-31 2024-05-24 西托姆克斯治疗公司 蛋白裂解酶和u型纤溶酶原激活物的底物和其它可裂解部分及其使用方法
GB201411506D0 (en) * 2014-06-27 2014-08-13 Univ London Queen Mary Modified latency associated protein construct
RU2714116C2 (ru) 2014-11-06 2020-02-11 Ф. Хоффманн-Ля Рош Аг ВАРИАНТЫ Fc-ОБЛАСТИ С МОДИФИЦИРОВАННЫМ СВЯЗЫВАНИЕМ FcRn И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MA41374A (fr) 2015-01-20 2017-11-28 Cytomx Therapeutics Inc Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci
WO2017190684A1 (zh) 2016-05-06 2017-11-09 王牧林 白细胞介素组合及其用途
JP7142630B2 (ja) 2016-10-14 2022-09-27 ゼンコア インコーポレイテッド ＩＬ１５／ＩＬ１５Ｒαヘテロ二量体ＦＣ－融合タンパク質
US20200123227A1 (en) 2017-06-20 2020-04-23 The Board Of Regents Of The University Of Texas System Interferon prodrug for the treatment of cancer
US11472889B2 (en) 2017-10-14 2022-10-18 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
CN111670051B (zh) 2017-11-08 2024-06-25 亚飞（上海）生物医药科技有限公司 生物分子偶联物及其用途
CN118373912A (zh) 2017-11-10 2024-07-23 新加坡科技研究局 IL2Rβ/共同γ链抗体
EP3727146A4 (en) 2017-12-19 2021-10-06 Blaze Bioscience, Inc. CELL PENETRATION PEPTIDE TUMOR AND IMMUNO-ONCOLOGY ADDRESSING AGENT COMPLEXES AND METHODS OF USE
WO2020113403A1 (en) 2018-12-04 2020-06-11 Beijing Percans Oncology Co. Ltd. Cytokine fusion proteins
CA3115461A1 (en) 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
CN113840832A (zh) 2018-05-14 2021-12-24 狼人治疗公司 可活化白介素-2多肽及其使用方法
WO2019222294A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP3816182A4 (en) 2018-05-30 2022-07-13 Chugai Seiyaku Kabushiki Kaisha LIGAND BINDING MOLECULE WITH SINGLE DOMAIN ANTIBODY
CA3103023A1 (en) 2018-06-21 2019-12-26 Tgw Logistics Group Gmbh Storage and order-picking system and method for picking ordered articles
JP7477885B2 (ja) 2018-06-22 2024-05-02 キュージーン インコーポレイテッド サイトカインをベースとした生理活性化薬剤およびその使用方法
CN112534052B (zh) 2018-07-25 2024-09-20 奥美药业有限公司 全新il-21前药及使用方法
CN112867503A (zh) 2018-08-24 2021-05-28 希望之城 掩蔽的细胞因子缀合物
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
EP3856229A1 (en) 2018-09-28 2021-08-04 Pierre Fabre Medicament New immunocytokines for the treatment of cancer
EP3870598A1 (en) 2018-10-23 2021-09-01 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins
MY205459A (en) 2018-12-06 2024-10-22 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine or cysteine protease-cleavable substrates and methods of use thereof
CA3121813A1 (en) 2018-12-14 2020-06-18 Proviva Therapeutics (Hong Kong) Limited Il-15 compositions and methods of use thereof
WO2020214690A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
CN113874390A (zh) 2019-05-24 2021-12-31 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
CN114127277A (zh) 2019-06-05 2022-03-01 中外制药株式会社 蛋白酶底物和包含蛋白酶切割序列的多肽
US11845801B2 (en) 2019-06-12 2023-12-19 AskGene Pharma, Inc. IL-15 prodrugs and methods of use thereof
CN119591725A (zh) 2019-07-12 2025-03-11 普罗维瓦疗法香港有限公司 Il-2组合物及其使用方法
EP4004026A4 (en) 2019-07-25 2023-11-15 Trutino Biosciences Inc. IL-2 CYTOKINE PRODRUGS WITH A CLAVEABLE LINKER
JP7682150B2 (ja) 2019-07-25 2025-05-23 ザ・ユニバーシティ・オブ・シカゴ プロテアーゼ活性化治療剤を含む組成物および方法
WO2021030483A1 (en) 2019-08-12 2021-02-18 AskGene Pharma, Inc. Il-2 fusion proteins that preferentially bind il-2ralpha
JP2022545439A (ja) 2019-08-21 2022-10-27 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－２１プロドラッグおよびその使用方法
EP4034551A1 (en) 2019-09-28 2022-08-03 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
JP2023503258A (ja) 2019-11-14 2023-01-27 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能サイトカインポリペプチド及びその使用方法
CN115315434A (zh) 2019-12-05 2022-11-08 免疫靶向有限公司 白细胞介素15融合蛋白和前药及其组合物和方法
EP4072593A4 (en) 2019-12-13 2024-01-03 Cugene Inc. BIOACTIVABLE CYTOKINE DRUGS AND ASSOCIATED METHODS OF USES
US12091440B2 (en) 2019-12-20 2024-09-17 Regeneron Pharmaceuticals, Inc. IL2 and peptide-MHC complex fusion proteins and methods of use thereof
BR112022013993A2 (pt) 2020-01-15 2022-10-11 Trutino Biosciences Inc Profármacos de citocina compreendendo um ligante clivável
US20230122079A1 (en) 2020-03-23 2023-04-20 Zymeworks Inc. Masked il12 fusion proteins and methods of use thereof
WO2021202354A1 (en) 2020-03-30 2021-10-07 Proviva Therapeutics (Hong Kong) Limited Il-2/il-15 compositions and methods of use thereof
WO2021202673A2 (en) 2020-04-01 2021-10-07 Xilio Development, Inc. Masked il-15 cytokines and their cleavage products
CN115734806A (zh) 2020-04-01 2023-03-03 西里欧发展公司 掩蔽的il-12细胞因子和其切割产物
KR20220161404A (ko) * 2020-04-01 2022-12-06 실리오 디벨럽먼트, 인크. 마스킹된 il-2 사이토카인 및 이들의 절단 산물
MX2022012592A (es) 2020-04-10 2022-12-07 Cytomx Therapeutics Inc Construcciones de citocinas activables y composiciones y metodos relacionados.
CN115996946A (zh) 2020-04-30 2023-04-21 免疫靶向有限公司 可活化il2组合物和使用方法
MX2022014411A (es) 2020-05-19 2023-01-24 Werewolf Therapeutics Inc Polipéptidos il-12 activables y métodos de uso de estos.
AU2022237504A1 (en) 2021-03-16 2023-10-05 Cytomx Therapeutics, Inc. Masked activatable cytokine constructs and related compositions and methods
CN120958015A (zh) * 2023-04-12 2025-11-14 西托姆克斯治疗公司 掩蔽多肽、可活化细胞因子构建体以及相关组合物和方法

Also Published As

Publication number Publication date
JP2023520922A (ja) 2023-05-22
US11365233B2 (en) 2022-06-21
CA3174786A1 (en) 2021-10-14
KR20220167295A (ko) 2022-12-20
IL297225A (en) 2022-12-01
AU2021254283B2 (en) 2025-12-11
US12091442B2 (en) 2024-09-17
WO2021207669A1 (en) 2021-10-14
AU2021254283A1 (en) 2022-11-10
US20210317177A1 (en) 2021-10-14
CN115667523A (zh) 2023-01-31
US20220402990A1 (en) 2022-12-22
EP4133085A1 (en) 2023-02-15
US20250179141A1 (en) 2025-06-05
BR112022020440A2 (pt) 2022-12-27

Similar Documents

Publication Publication Date Title
MX2022012592A (es) Construcciones de citocinas activables y composiciones y metodos relacionados.
WO2022197764A3 (en) Masked activatable cytokine constructs and related compositions and methods
MX2024004301A (es) Construcciones de citocinas activables y metodos combinados.
WO2023060156A3 (en) Activatable cytokine constructs and related compositions and methods
CN102148563B (zh) 一种跟踪电源、电源控制方法及通信设备
CN102142768B (zh) 一种快速跟踪电源装置、控制方法及通信设备
CN103166435B (zh) 一种基于igbt串联损耗优化电压自适应控制方法
TW200518535A (en) High performance modulator architecture for the outphasing rf amplifier
CN104993796B (zh) 一种Doherty功率放大器
CN101783652A (zh) 一种易于实现的多级Doherty功放
US8773206B2 (en) Power amplifier apparatus and power amplifier circuit
WO2022216386A3 (en) T-type calcium channel antagonists and uses thereof
CN205195668U (zh) 一种s波段测波雷达功率放大器装置
CN201499137U (zh) 功率放大器
CN101662222B (zh) 电源跟踪方法和装置
CN201113924Y (zh) 带直流偏置的二极管双平衡混频器
GB672865A (en) Improvements in and relating to radio ranging systems
CN104836536A (zh) 一种基于负反馈的功率放大器结构
WO2023010083A3 (en) Recombinant prenyltransferase polypeptides engineered for enhanced biosynthesis of cannabinoids
US12519427B2 (en) Envelope controlled biasing of an auxiliary transmitter of a doherty power amplifier
CN208608971U (zh) 一种氮化镓微波集成电路脉冲调制电路
AR125090A1 (es) Construcciones de citoquinas activables enmascaradas y composiciones y métodos relacionados
CN110635667B (zh) 一种用于包络跟踪系统的三电平滞回控制电源调制器
CN205545167U (zh) 双模功率放大器
CN206422751U (zh) 一种x波段固态功率放大器